Conditions: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Keywords: breast cancer triple negative androgen receptor positive
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 118
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor and are not Her2 amplified.

Detailed description:

Arms:
arm 1: 160 mg administered as four 40 mg soft gelatin capsules orally once daily

Interventions: intervention 1: Enzalutamide
Intervention descriptions: intervention 1: 160 mg administered as four soft gelatin capsules orally once daily

Protocol document: